Abstract:Activating mutations of NRAS are found in 20%–40% of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelodysplastic syndrome (MDS). Like all RAS proteins, oncogenic NRAS must undergo a series of post-translational modifications for differential targeting to distinct cellular microdomains. NRAS is first farnesylated, then subsequently cleaved and methylated at its C-terminal -CAAX region, and is finally reversibly palmitoylated, with each modification catalyzed by a distinct enzyme(s). Once targeted to plasma membrane and/or endomembranes, NRAS engages local activators/effectors to generate distinct signaling outputs that govern cell survival, proliferation and differentiation. The requirement of membrane attachment for transforming activity by RAS oncoproteins makes RAS modification enzymes attractive targets for the development of cancer therapies. To date, however, success of therapies targeting the obligatory first step in the series of RAS post-translational modifications by targeting farnesyl protein transferase have been modest (KRAS and NRAS may alternatively prenylated via geranylgeranylation). Additionally it has been unclear whether RAS is the target affected by blocking farnsylation using inhibitors, since many proteins are modified in this way. Other RAS modifications such as palmitoylation (for HRAS and NRAS) may be more specific (a smaller number of proteins contain -CAAX motifs that are both prenylated and methylated, both of which are thought to be required for palmitoyltransferase activity) and are required for optimal plasma membrane association and targeting of RAS to specific membrane subdomains. However, inconsistent results have been reported as to the relative importance of these latter modifications on RAS function and transforming ability. We have previously shown that expression of oncogenic NRAS in a bone marrow transduction/transplantation model system induces an AML- or CMML-like disease in mice. Using this model in conjunction with mutational analysis of specific post-translational modification sites on the oncogene, we have observed the effect of specifically blocking the palmitoylation modification to oncogenic NRAS in NRAS leukemogenesis. Unlike mutation to the farnesylation site, which causes dislocalization from membranes entirely, the palmitoylation mutation redistributes oncogenic NRAS to internal membranes, indicating that the oncoprotein may retain signaling capacity. However, we find that some signaling pathways upregulated by oncogenic NRAS including the RAS-RAF-MEK-ERK signaling pathway are returned to normal nontransforming signaling levels in cells expressing oncogenic NRAS with the palmitoylation mutation. Furthermore, like farnesylation, we find palmitoylation to be essential for leukemogenesis by oncogenic NRAS in our mouse bone marrow transduction/transplantation model. This study sheds new light on the mechanism of NRAS leukemogenesis and suggests that the palmitoyltransferase enzyme for NRAS may be an effective target for developing therapeutics for hematological malignancies.

Control of the signaling of RAS proteins by modulating their palmitoylation

Regulation of RAS palmitoyltransferases by accessory proteins and palmitoylation

Reversible control of kinase signaling through chemical-induced dephosphorylation

Bioprotacs Establish RAS As a Degradable Target and Provide Novel RAS Biology Insights

A mechanism regulating G protein-coupled receptor signaling that requires cycles of protein palmitoylation and depalmitoylation

Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket

Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling

Degradation of Rat Sarcoma Proteins Targeting the Post-Translational Prenyl Modifications Via Cascade Azidation/Fluorination and Click Reaction

One Step Closer to Targeting RAS.

Palmitoylation of Oncogenic NRAS is Essential for Leukemogenesis

ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth

Drugging the undruggable RAS: Mission Possible?

Drugging Ras Gtpase: A Comprehensive Mechanistic And Signaling Structural View

Discovery of Covalent NRAS Inhibitors Targeting the Palmitoylation Site Through Imaging-Based High-Throughput Screening

Drugging Ras GTPase: a Comprehensive Mechanistic and Signaling Structural View.

Reversible Small Molecule pan-Ras Inhibitors Display Tunable Affinity for the Active and Inactive forms of Ras.

Developing Small Molecules that Inhibit K-Ras/GTP Binding Based on New Affinity Measurements

Regulation of Prenylated Rat Sarcoma Proteins Via Sequential Azidation-Selenylation and a Click Reaction

Dominant Negative Effect Of Palmitoylation-Deficient Nras In Suppression Of Bcr/Abl Leukemogenesis

Controlling Kinase Activities by Selective Inhibition of Peptide Substrates